Eva Corey

Research interests

Publications

• MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets

  Nature Communications · 2022 · 10.1038/s41467-022-30257-z

• Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer

  Cancer Research · 2021 · 10.1158/0008-5472.can-20-3477

• Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer

  Nature Communications · 2021 · 10.1038/s41467-021-26042-z

• Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer

  Nature Communications · 2021 · 10.1038/s41467-021-22139-7

• Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress

  Cell Reports · 2020 · 10.1016/j.celrep.2020.107669

• Prostate cancer reactivates developmental epigenomic programs during metastatic progression

  Nature Genetics · 2020 · https://doi.org/10.1038/s41588-020-0664-8

• Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer

  Journal of Clinical Investigation · 2019 · https://doi.org/10.1172/jci128212

• A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

  Clinical Cancer Research · 2018 · 10.1158/1078-0432.ccr-18-0409

• ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis

  Nature Medicine · 2018 · 10.1038/s41591-018-0241-1

• LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics

  The Prostate · 2017 · 10.1002/pros.23313

• Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models

  Clinical Cancer Research · 2017 · 10.1158/1078-0432.ccr-16-2955

• Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling

  Cancer Cell · 2017 · https://doi.org/10.1016/j.ccell.2017.09.003

• SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer

  Clinical Cancer Research · 2015 · 10.1158/1078-0432.ccr-15-0157

• Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer

  Cancer Research · 2014 · 10.1158/0008-5472.can-13-2876

• The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis

  Cancer Discovery · 2014 · https://doi.org/10.1158/2159-8290.cd-13-1010

• Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer

  Nature Communications · 2014 · 10.1038/ncomms5988

• Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers

  Proceedings of the National Academy of Sciences · 2011 · 10.1073/pnas.1108745108

• Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

  Current Cancer Drug Targets · 2009 · 10.2174/156800909787580999

• Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1

  Nature Medicine · 2007 · https://doi.org/10.1038/nm1677

• Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases

  Clinical Cancer Research · 2006 · https://doi.org/10.1158/1078-0432.ccr-06-1007

• Cathepsin K mRNA and Protein Expression in Prostate Cancer Progression

  Journal of Bone and Mineral Research · 2003 · 10.1359/jbmr.2003.18.2.222

• Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.

  PubMed · 2003

• Elevation of cytokine levels in cachectic patients with prostate carcinoma

  Cancer · 2003 · 10.1002/cncr.11178

• Establishment and characterization of osseous prostate cancer models: Intra‐tibial injection of human prostate cancer cells

  The Prostate · 2002 · 10.1002/pros.10091

• Osteoprotegerin and rank ligand expression in prostate cancer

  Urology · 2001 · 10.1016/s0090-4295(00)01122-5

Current projects

No projects listed.